Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E M Rankin

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Reconstitution of recombinant interleukin-2 (rIL-2): a comparative study of various rIL-2 muteinsL T Vlasveld, J H Beijnen, J J Sein, et al.
European Journal of Nuclear Medicine|June 1, 1994
Sensitivity versus specificity in melanoma imaging using iodine-123 iodobenzamide and indium-111 pentetreotideC A Hoefnagel, E M Rankin, R A Valdés Olmos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1994
Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancerL T Vlasveld, S Horenblas, A Hekman, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
Phase I clinical and pharmacokinetic study of LY 195448J Cassidy, C Lewis, L Adams, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 1, 1994
Catheter-related complications in 52 patients treated with continuous infusion of low dose recombinant interleukin-2 via an implanted central venous catheterL T Vlasveld, S Rodenhuis, E J Rutgers, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Phase I clinical study of LL-D49194 alpha 1 with retrospective pharmacokinetic investigations in mice and humans. The EORTC ECTGJ Cassidy, M A Graham, W Ten Bokkel Huinink, et al.
British Journal of Cancer|November 1, 1988
Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonistJ Cassidy, V Raina, C Lewis, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Phase I and pharmacokinetic study of intraperitoneal thioTEPA in patients with ovarian cancerC Lewis, N Lawson, E M Rankin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 1, 1996
IL-1 beta does not cause neutrophil degranulation but does lead to IL-6, IL-8, and nitrite/nitrate release when used in patients with cancerA C Ogilvie, C E Hack, J Wagstaff, et al.
British Journal of Cancer|November 1, 1993
Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumoursM W Dercksen, K Hoekman, W W ten Bokkel Huinink, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Reconstitution of recombinant interleukin-2 (rIL-2): a comparative study of various rIL-2 muteinsL T Vlasveld, J H Beijnen, J J Sein, et al.
European Journal of Nuclear Medicine|June 1, 1994
Sensitivity versus specificity in melanoma imaging using iodine-123 iodobenzamide and indium-111 pentetreotideC A Hoefnagel, E M Rankin, R A Valdés Olmos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1994
Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancerL T Vlasveld, S Horenblas, A Hekman, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
Phase I clinical and pharmacokinetic study of LY 195448J Cassidy, C Lewis, L Adams, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 1, 1994
Catheter-related complications in 52 patients treated with continuous infusion of low dose recombinant interleukin-2 via an implanted central venous catheterL T Vlasveld, S Rodenhuis, E J Rutgers, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Phase I clinical study of LL-D49194 alpha 1 with retrospective pharmacokinetic investigations in mice and humans. The EORTC ECTGJ Cassidy, M A Graham, W Ten Bokkel Huinink, et al.
British Journal of Cancer|November 1, 1988
Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonistJ Cassidy, V Raina, C Lewis, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Phase I and pharmacokinetic study of intraperitoneal thioTEPA in patients with ovarian cancerC Lewis, N Lawson, E M Rankin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 1, 1996
IL-1 beta does not cause neutrophil degranulation but does lead to IL-6, IL-8, and nitrite/nitrate release when used in patients with cancerA C Ogilvie, C E Hack, J Wagstaff, et al.
British Journal of Cancer|November 1, 1993
Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumoursM W Dercksen, K Hoekman, W W ten Bokkel Huinink, et al.
Pageof 6